Webinar - Overcome Perceived DCT and eCOA Adoption Hurdles
May 12, 2021
With more patients at home than in sites, DCTs armed with flexible, easy to use eCOA technologies with TeleCOA capabilities are more vital than ever in ensuring trials maintain data quality with fewer deviations and missed appointments.
Please login to view video - or subscribe here
More than anything else, 2020 has proven that clinical needs flexibility. In the face of adversity, trial solutions just don’t meet the needs of study teams. With more patients at home than in sites, DCTs armed with flexible, easy to use eCOA technologies with TeleCOA capabilities are more vital than ever in ensuring trials maintain data quality with fewer deviations and missed appointments.
Join Brittany Murphy, PPD, Kai Langel, Janssen, Anne Marie Inglis, Mallinckrodt, Tero Laulajainen, UCB Alison Holland Head of Decentralized Clinical Trials, Medable, and Rasmus Hogreffe, VP of Decentralized Clinical trial Innovation, Medable as they explore common myths and roadblocks around DCTs and eCOA including:
• Why DCT Technology can’t be incorporated into therapies traditionally viewed as having toxicity that prevents decentralization (e.g. Oncology)
• How adding technology often makes study operations worse for older participants
• Why eCOA and DCT technology requires multiple vendors and platforms but still need to be ‘one size fits all’ within a study
Reuters Events Pharma’s youtube channel now broadcasts the best presentations, chats and interviews from our conferences.
Reuters Events Pharma’s mission is to make the pharmaceutical industry more open and valued. Our conferences are where leading minds gather to discuss and share strategies that drive value for patients and shine a light on pharma excellence. Look for talks on patient-centricity, digital marketing, RWE, cell & gene therapy, access, diversity, clinical innovation and medical affairs.
Subscribe to our channel: https://www.youtube.com/c/Eyeforpharm...